Rational design, efficient syntheses and biological evaluation of N,N '-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F13%3A00394149" target="_blank" >RIV/61388963:_____/13:00394149 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1016/j.ejmech.2012.12.044" target="_blank" >http://dx.doi.org/10.1016/j.ejmech.2012.12.044</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejmech.2012.12.044" target="_blank" >10.1016/j.ejmech.2012.12.044</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Rational design, efficient syntheses and biological evaluation of N,N '-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers
Popis výsledku v původním jazyce
A series of symmetrically his-substituted imidazole analogs bearing at the N-1 and N-3 two biphenyl moieties ortho substituted either with tetrazole or carboxylate functional groups was designed based on docking studies and utilizing for the first time an extra hydrophobic binding cleft of AT1 receptor. The synthesized analogs were evaluated for their in vitro antagonistic activities (pA(2) values) and binding affinities (-logIC(50) values) to the Angiotensin II AT1 receptor. Among them, the potassium (-logIC(50)= 9.04) and the sodium (-logIC(50) = 8.54) salts of 4-butyl-N,N'-bis{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl} imidazolium bromide (12a and 12b, respectively) as well as its free acid 11 (-logIC(50) = 9.46) and the 4-butyl-2-hydroxymethyl-N,N'-bis{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}imidazolium bromide (14) (-logIC(50)= 8.37, pA(2) = 8.58) showed high binding affinity to the AT1 receptor and high antagonistic activity (potency). The potency was similar or even superior
Název v anglickém jazyce
Rational design, efficient syntheses and biological evaluation of N,N '-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers
Popis výsledku anglicky
A series of symmetrically his-substituted imidazole analogs bearing at the N-1 and N-3 two biphenyl moieties ortho substituted either with tetrazole or carboxylate functional groups was designed based on docking studies and utilizing for the first time an extra hydrophobic binding cleft of AT1 receptor. The synthesized analogs were evaluated for their in vitro antagonistic activities (pA(2) values) and binding affinities (-logIC(50) values) to the Angiotensin II AT1 receptor. Among them, the potassium (-logIC(50)= 9.04) and the sodium (-logIC(50) = 8.54) salts of 4-butyl-N,N'-bis{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl} imidazolium bromide (12a and 12b, respectively) as well as its free acid 11 (-logIC(50) = 9.46) and the 4-butyl-2-hydroxymethyl-N,N'-bis{[2'-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}imidazolium bromide (14) (-logIC(50)= 8.37, pA(2) = 8.58) showed high binding affinity to the AT1 receptor and high antagonistic activity (potency). The potency was similar or even superior
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
CC - Organická chemie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
European Journal of Medicinal Chemistry
ISSN
0223-5234
e-ISSN
—
Svazek periodika
62
Číslo periodika v rámci svazku
Apr
Stát vydavatele periodika
FR - Francouzská republika
Počet stran výsledku
19
Strana od-do
352-370
Kód UT WoS článku
000318577500037
EID výsledku v databázi Scopus
—